Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.47 |
| ▸ | GHSR | Q92847 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.30 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119014 | 0.87 | NAALAD2 (0.45) | NAALAD2GHSRMAPTALOX15KMT2A | |
| SCHEMBL13775773 | 0.73 | GHSR (0.32) | GHSR | |
| SCHEMBL7341365 | 0.72 | NAALAD2 (0.50) | NAALAD2GHSRMAPTFAAHTDP1 | |
| SCHEMBL21515089 | 0.71 | NAALAD2 (0.60) | NAALAD2GHSRTDP1 | |
| SCHEMBL28504133 | 0.71 | NAALAD2 (0.60) | NAALAD2GHSRTDP1 | |
| SCHEMBL22069732 | 0.70 | NAALAD2 (0.51) | NAALAD2GHSRGLATSHR | |
| SCHEMBL13344348 | 0.70 | NAALAD2 (0.48) | NAALAD2GHSRKMT2AGLATSHR | |
| Hydrochloric Acid SCHEMBL21494731 | 0.70 | NAALAD2 (0.58) | NAALAD2GHSRTDP1 | |
| Hydrochloric Acid SCHEMBL28501489 | 0.70 | NAALAD2 (0.58) | NAALAD2GHSRTDP1 | |
| SCHEMBL21515088 | 0.69 | NAALAD2 (0.60) | NAALAD2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | NAALAD2 1319/4885GHSR 796/4885MAPT 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.